PCSK9 concentrations in different stages of subclinical atherosclerosis and their relationship with inflammation

被引:1
|
作者
Toth, Stefan [1 ]
Olexa, Peter [1 ]
Hertelyova, Zdenka [2 ]
Stefanic, Peter [3 ]
Kopolovets, Ivan [3 ]
Berek, Peter [3 ]
Filip, Vladimir [4 ]
Chakravarty, Ryan [1 ]
Siroka, Monika [5 ]
Pella, Daniel [6 ,7 ]
机构
[1] Pavol Jozef Safarik Univ, Air Force Mil Hosp, Fac Med, Dept Gerontol & Geriatr, Murgasova 1, Kosice 04086, Slovakia
[2] Pavol Jozef Safarik Univ, Dept Expt Med, Fac Med, Trieda SNP 1, Kosice 04190, Slovakia
[3] East Slovak Inst Cardiovasc Dis, Dept Vasc Surg, Ondavska 8, Kosice 04011, Slovakia
[4] Pavol Jozef Safarik Univ, Louis Pasteur Univ Hosp, Dept Orthopaed & Traumatol Locomotory Apparat, Trieda SNP 1, Kosice 04190, Slovakia
[5] Pavol Jozef Safarik Univ, Fac Med, Dept Med & Clin Biochem, Trieda SNP 1, Kosice 04190, Slovakia
[6] Pavol Jozef Safarik Univ, Fac Med, Dept Cardiol 2, Ondavska 8, Kosice 04011, Slovakia
[7] East Slovak Inst Cardiovasc Dis, Ondavska 8, Kosice 04011, Slovakia
来源
OPEN CHEMISTRY | 2020年 / 18卷 / 01期
关键词
PCSK9; inflammation; atherosclerosis; plaque; initiation; INTIMA-MEDIA THICKNESS; PLASMA PCSK9; RISK; EVOLOCUMAB; STIFFNESS; DISEASE;
D O I
10.1515/chem-2020-0147
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The aim of this study was to detect the concentrations of PCSK9 in various subclinical stages of atherosclerosis and to highlight its relationship with inflammation. One hundred and fifty-nine healthy patients were divided into three groups, based on the extent of atherosclerotic changes in the carotid artery: a group without identifiable atherosclerosis, cIMT(>)(75 parts per thousand) and an asymptomatic plaque group. The PCSK9 was measured by ELISA and hsCRP by the immunoturbidimetric method. Vascular changes were identified by a carotid ultrasound. PCSK9 was elevated, when comparing the healthy group with the cIMT(>75 parts per thousand) group; however, no significant increase was detected between cIMT(>75 parts per thousand) and the asymptomatic plaque group. A positive linear correlation of the PCSK9 concentration and atherosclerotic changes was found; however, after the re-analysis in each group, this correlation persisted only in the group with still normal values. Additionally, a significant linear correlation was found between the PCSK9 concentrations and lipid parameters. However, no significant association was found with hsCRP. PCSK9 was found to be elevated only in cIMT(>75 parts per thousand), but not in the later plaque stage. A linear correlation of PCSK9 values was detected only in the group with still reference values. Based on this fact, we assumed the direct linear role of PCSK9 in initiating atherosclerosis; however, in the later phases, the relationship, which highlights other risk factors such as inflammation, is not linear.
引用
收藏
页码:1011 / 1019
页数:9
相关论文
共 50 条
  • [31] PCSK9 inhibition might increase endothelial inflammation
    Schmid, Johannes A.
    ATHEROSCLEROSIS, 2022, 362 : 26 - 28
  • [32] PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
    Luquero, Aureli
    Badimon, Lina
    Borrell-Pages, Maria
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [33] Correlations of PCSK9 and LDLR Gene Polymorphisms and Serum PCSK9 Levels With Atherosclerosis and Lipid Metabolism in Patients on Maintenance Hemodialysis
    Cui, Jun
    Qiu, Yuxiang
    Kang, Ningsu
    Lu, Jianxun
    Zheng, Lu
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (12) : 1430 - 1437
  • [34] Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes
    Liberale, Luca
    Montecucco, Fabrizio
    Camici, Giovanni G.
    Dallegri, Franco
    Vecchie, Alessandra
    Carbone, Federico
    Bonaventura, Aldo
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (14) : 1403 - 1416
  • [35] Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes
    Heena Agarwal
    Brea Tinsley
    Amesh K. Sarecha
    Lale Ozcan
    Current Atherosclerosis Reports, 2023, 25 : 931 - 937
  • [36] R46L polymorphism in the PCSK9 gene: Relationship to lipid levels, subclinical vascular disease, and erectile dysfunction
    Mostaza, Jose M.
    Lahoz, Carlos
    Salinero-Fort, Miguel A.
    de Dios, Olaya
    Castillo, Elisa
    Gonzalez-Alegre, Teresa
    Garcia-Iglesias, Francisca
    Estirado, Eva
    Laguna, Fernando
    Sabin, Concesa
    Lopez, Silvia
    Cornejo, Victor
    de Burgos, Carmen
    Sanchez, Vanesa
    Garces, Carmen
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (04) : 1039 - 1046
  • [37] PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials
    Luo, Jichang
    Liao, Wanying
    Wang, Xue
    Xu, Ran
    Li, Wei
    Li, Wenjing
    Liu, Kan
    Huang, Kaixun
    Ma, Yan
    Wang, Tao
    Yang, Bin
    Jiao, Liqun
    BMJ OPEN, 2022, 12 (11):
  • [38] Disruption of PCSK9 Suppresses Inflammation and Attenuates Abdominal Aortic Aneurysm Formation
    Peng, Zekun
    Lv, Shuang-Jie
    Chen, Hong
    Rao, Haojie
    Guo, Ziyi
    Wan, Qing
    Yang, Jianfeng
    Zhang, Yuze
    Liu, De-Pei
    Chen, Hou-Zao
    Wang, Miao
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2025, 45 (01) : e1 - e14
  • [39] Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke
    Zhang, Lingling
    Song, Kangping
    Zhu, Mengting
    Shi, Jinling
    Zhang, Huijuan
    Xu, Liang
    Chen, Yingzhu
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2016, 126 (08) : 675 - 680
  • [40] From Endothelium to Lipids, Through microRNAs and PCSK9: A Fascinating Travel Across Atherosclerosis
    D'Ardes, D.
    Santilli, F.
    Guagnano, M. T.
    Bucci, M.
    Cipollone, F.
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2020, 27 (01) : 1 - 8